Clinical utility of targeted next generation sequencing (NGS) to predict response to neoadjuvant therapy (NT) in rectal cancer (RC).

Authors

null

Kristen Carroll

Northwestern University, Feinberg School of Medicine, Chicago, IL

Kristen Carroll , Michael C. Burns , Ryan Jones , Masha Kocherginsky , Kirsten Bell Burdett , Guang-Yu Yang , Al Bowen Benson III, Devalingam Mahalingam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 237)

Abstract #

237

Poster Bd #

L15

Abstract Disclosures

Similar Posters

First Author: Michael C. Burns

Poster

2018 ASCO Annual Meeting

Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.

Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.

First Author: Razelle Kurzrock